Many vaccines and drugs hold the promise of reducing mortality and morbidity among pregnant women and infants living in low- and middle-income countries (LMICs). However, sufficient information on the safety of drugs and vaccines in pregnant women is rarely available at the time of product licensure or approval.
This Guidance for country COVID-19 after action review (AAR) aims to support countries in achieving this recommendation to systematically review their respective responses to COVID-19. It provides step-by-step instructions and relevant tools to conduct a country COVID-19 AAR.